Roche's Xeloda Shows Significant Survival Benefit In Pancreatic Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Combo therapy of Xeloda plus gemcitabine shows median survival of 7.4 months versus six months with Gemzar alone.